天士力(600535.SH)擬分拆天士力生物至上交所科創板上市
格隆匯 11 月 17日丨天士力(600535.SH)公佈,公司擬將控股子公司天士力生物分拆至上交所科創板上市。此次分拆完成後,天士力股權結構不會發生變化,且仍將維持對天士力生物的控股權。
通過此次分拆上市,天士力生物將得以充實資本實力,加大產品的研發投入及營銷活動投入,有助於增強天士力生物核心競爭力,進而強化其在生物藥領域的行業地位、市場份額及盈利能力,有效深化在生物藥領域的戰略佈局,能夠進一步提升公司資產質量和風險防範能力,增強天士力生物綜合優勢,促進持續健康的長遠發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.